NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Nymox Pharmaceutical
Corporation ("Nymox" or the "Company") (NASDAQ: NYMX). Such
investors are advised to contact Robert S.
Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
9980.
[Click here to join a class action]
The investigation concerns whether Nymox and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On August 10, 2016, Seeking
Alpha published an article entitled "Nymox: This Offshore
'Biotech' Promotion Will Go To Zero (Yes, Zero)", reporting that
Nymox management has consistently misled shareholders about the
Company's prospects while "aggressively dump[ing] stock without
timely SEC disclosure."
On this news, Nymox stock has fallen as much as $1.47, or 47.27%, to $1.64 during intraday trading on August 10, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-nymox-pharmaceutical-corporation---nymx-300312089.html
SOURCE Pomerantz LLP